![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Sofosbuvir and Ribavirin for the Treatment of Chronic HCV With Cirrhosis and Portal Hypertension With and Without Decompensation: Early Virologic Response and Safety
|
|
|
Reported by Jules Levin
EASL 2014 April 9-13 London, UK
Nezam Afdhal,1 Gregory Everson,2 Jose Luis Calleja,3 Geoffrey McCaughan,4
William T Symonds,5 Diana Brainard,5 Jill Denning,5 Theo Brandt-Sarif,5 Lindsay McNair,5 John G. McHutchison,5 Sarah Arterburn,5 Jaime Bosch,10 Michael Charlton,6 Rajender Reddy,7 Tarik Asselah,8 Edward Gane,9 Xavier Forns10
1Beth Israel Deaconess Medical Center, Boston, MA, USA; 2University of Colorado Denver, Aurora, USA; 3Hospital Puerta de Hierro, Madrid, Spain; 4Royal Prince Alfred Hospital, University of Sydney, New South Wales, Australia; 5Gilead Sciences, Inc., Foster City, CA, USA; 6Mayo Clinic, Rochester, MN, USA; 7University of Pennsylvania, Philadelphia, USA; 8Hopital Beaujon, INSERM U773 and
University Paris-Diderot, Clichy, France; 9Auckland City Hospital, Grafton, Auckland, New Zealand; 10Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, and Centro de Investigacion Biomedica en Red de Enfermedades Hepáticas y Digestivas, Barcelona, Spain
![EASL1.gif](../images/041114/041114-12/EASL1.gif)
![EASL2.gif](../images/041114/041114-12/EASL2.gif)
![EASL3.gif](../images/041114/041114-12/EASL3.gif)
![EASL4.gif](../images/041114/041114-12/EASL4.gif)
![EASL5.gif](../images/041114/041114-12/EASL5.gif)
![EASL6.gif](../images/041114/041114-12/EASL6.gif)
![EASL7.gif](../images/041114/041114-12/EASL7.gif)
![EASL8.gif](../images/041114/041114-12/EASL8.gif)
![EASL9.gif](../images/041114/041114-12/EASL9.gif)
![EASL10.gif](../images/041114/041114-12/EASL10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|